SG11201407326XA - Compositions and methods for treatment of mucositis - Google Patents

Compositions and methods for treatment of mucositis

Info

Publication number
SG11201407326XA
SG11201407326XA SG11201407326XA SG11201407326XA SG11201407326XA SG 11201407326X A SG11201407326X A SG 11201407326XA SG 11201407326X A SG11201407326X A SG 11201407326XA SG 11201407326X A SG11201407326X A SG 11201407326XA SG 11201407326X A SG11201407326X A SG 11201407326XA
Authority
SG
Singapore
Prior art keywords
international
treatment
compositions
publication
mucositis
Prior art date
Application number
SG11201407326XA
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of SG11201407326XA publication Critical patent/SG11201407326XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/48—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/175377 A3 (51) International Patent Classification: C07D 205/06 (2006.01) A61P1/04 (2006.01) C07D 295/12 (2006.01) A61K31/155 (2006.01) A61P1/00 (2006.01) A61K31/445 (2006.01) A61P1/02 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/IB2013/054098 19 May 2013 (19.05.2013) English English (30) Priority Data: 2057/CHE/2102 23 May 2012 (23.05.2012) IN (72) Inventor; and (71) Applicant : KANDULA, Mahesh [IN/IN]; Door No. 11- 61, Samalkot Mandal, East Godavari Dist, G.Medapadu 533 434, Andhra Pradesh (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (88) Date of publication of the international search report: 30 January 2014 l> l> m i> i-H cn i-H o CJ (54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF MUCOSITIS (57) Abstract: The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of com­ pounds of formula (I), and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus dis­ eases related painful inflammation and ulceration of to the digestive tract lining and in the mouth.
SG11201407326XA 2012-05-23 2013-05-19 Compositions and methods for treatment of mucositis SG11201407326XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2057CH2012 2012-05-23
PCT/IB2013/054098 WO2013175377A2 (en) 2012-05-23 2013-05-19 Compositions and methods for the treatment of mucositis

Publications (1)

Publication Number Publication Date
SG11201407326XA true SG11201407326XA (en) 2014-12-30

Family

ID=53097332

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407326XA SG11201407326XA (en) 2012-05-23 2013-05-19 Compositions and methods for treatment of mucositis

Country Status (9)

Country Link
US (2) US9765020B2 (en)
EP (1) EP2852571A4 (en)
JP (1) JP2015518855A (en)
CN (1) CN104583182A (en)
AU (1) AU2013264820A1 (en)
CA (1) CA2873104A1 (en)
SG (1) SG11201407326XA (en)
WO (1) WO2013175377A2 (en)
ZA (1) ZA201408056B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014091384A2 (en) * 2012-12-12 2014-06-19 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
JP6564868B2 (en) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ Three component salts of fumaric acid monomethyl ester and piperazine or ethylenediamine for the treatment of multiple sclerosis
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (en) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
JP6975165B2 (en) * 2015-12-16 2021-12-01 ニューロフィシア・ベー・フェー 2-Iminobiotin for use in the treatment of brain cell injury
CN105963799A (en) * 2016-06-16 2016-09-28 湖州科达化工燃料有限公司 Anti-infection anti-adhesion membrane
CA3116157A1 (en) * 2018-10-17 2020-04-23 Lakewood Amedex, Inc. Methods and compositions for treating oral mucositis

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2807644A (en) 1954-08-20 1957-09-24 Parke Davis & Co Pantethine inhibitors
DE1205972B (en) 1963-08-20 1965-12-02 Merck Ag E Process for the production of a lipoic acid derivative
US4011342A (en) * 1971-06-02 1977-03-08 Seperic Method and composition for the treatment of hypertension with ortho-disubstituted arylguanidines
GB1356470A (en) * 1971-06-02 1974-06-12 Seperic Ortho-disubstituted aryl-guanidines process for their preparation and applications thereof
CA1081709A (en) * 1975-07-11 1980-07-15 Julius Diamond Phenylamidino urea compounds
JPS5677259A (en) 1979-11-29 1981-06-25 Nippon Chemiphar Co Ltd N-pyridoxyl 5,8,11,14,17-eicosapentaenoic acid amide, and its preparation
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4404366A (en) 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4440763A (en) 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
IT1190727B (en) 1982-03-10 1988-02-24 Ausonia Farma Srl COMPOUND WITH ANALGESIC, ANTI-INFLAMMATORY AND MUCOREGULATING ACTIVITY PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
FR2528038B2 (en) 1982-06-04 1985-08-09 Lafon Labor BENZHYDRYLSULFINYLACETAMIDE DERIVATIVES AND THEIR THERAPEUTIC USE
US4564628A (en) 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US5104887A (en) 1983-02-04 1992-04-14 University Of Iowa Research Foundation Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors
JPS6089474A (en) 1983-10-20 1985-05-20 Toyo Pharma- Kk Morphinan derivative, production thereof and antitumor agent containing said compound
IL73293A (en) 1983-11-04 1988-02-29 Abbott Lab Methyl 2-(alkanamidoalkylsulfonic)ethylthiophosphonate derivatives
IT1213132B (en) 1984-02-02 1989-12-14 Yason Srl ANTIBRONCOPNEUMOPATHIC AGENT.
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
JPS61277618A (en) 1985-06-04 1986-12-08 Suntory Ltd Remedy for autism
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
DE69016335T2 (en) 1989-10-06 1995-06-01 Fujirebio Kk Pantothenic acid derivatives.
US5242937A (en) 1990-03-19 1993-09-07 Research Corporation Technologies, Inc. Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors
IT1248702B (en) 1990-06-06 1995-01-26 Yason Srl ANTITUSSIVE AGENT AND MUCOREGULATOR, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS
FR2699077B1 (en) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application of anticonvulsants in the treatment of neurological lesions linked to trauma.
FR2707637B1 (en) 1993-06-30 1995-10-06 Lafon Labor New acetamide derivatives, their preparation process and their use in therapy.
WO1995022546A1 (en) 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
SE9401727D0 (en) 1994-05-18 1994-05-18 Astra Ab New compounds I
FR2722199B3 (en) 1994-07-11 1996-09-06 Univ Picardie Jules Verne Etab VALPROIC ACID DERIVATIVES AND THEIR APPLICATIONS AS MEDICAMENTS
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
NZ334389A (en) 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
CA2272065A1 (en) 1996-11-22 1998-05-28 Thomas E. Mabry N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
WO1999043648A1 (en) 1998-02-27 1999-09-02 Sankyo Company, Limited Cyclic amino compounds
JP3761324B2 (en) 1998-05-15 2006-03-29 ヤンマー農機株式会社 Passenger rice transplanter
US6846495B2 (en) 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
PT1466889E (en) 1999-04-06 2008-07-02 Sepracor Inc O-desmethylvenlafaxine succinate
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
WO2001022967A1 (en) 1999-09-29 2001-04-05 The Procter & Gamble Company Compositions having improved stability
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
AU2001279064A1 (en) 2000-07-27 2002-02-13 Rutgers, The State University Therapeutic azo-compounds for drug delivery
KR100810930B1 (en) 2000-10-24 2008-03-10 아지노모토 가부시키가이샤 Process for producing B-form nateglinide crystal
MXPA03004546A (en) * 2000-11-22 2003-09-10 Rxkinetix Inc Treatment of mucositis.
DE10103506A1 (en) 2001-01-26 2002-08-14 Ingo S Neu Pharmaceutical composition for the treatment of multiple sclerosis
UA81224C2 (en) 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
CN1612732A (en) 2001-08-29 2005-05-04 恩德制药公司 Analgesics and methods of use
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
EP1497258A1 (en) 2002-04-15 2005-01-19 Novartis AG Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
IL164185A0 (en) 2002-04-16 2005-12-18 Fujisawa Pharmaceutical Co Pharmaceutical compositions containing trifluoromethylphenyl amide derivatives
US7060725B2 (en) 2002-05-13 2006-06-13 Janssen Pharmaceutica N.V. Substituted sulfamate anticonvulsant derivatives
GB0223224D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
EP1988397B8 (en) 2002-12-19 2012-02-15 The Scripps Research Institute Compositions and uses for stabilising transthyretin and inhibiting transthyretin misfolding
WO2004075886A1 (en) 2003-02-14 2004-09-10 Pierre Fabre Medicament Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
UA81657C2 (en) 2003-03-04 2008-01-25 Орто-Макнейл Фармасьютикел, Инк. Normal;heading 1;heading 2;PROCESS FOR THE PREPARATION OF ANTICONVULSANT DERIVATIVES OF TOPIRAMATE
NZ545570A (en) 2003-07-29 2012-07-27 Signature R & D Holdings Llc Amino acid prodrugs
SG147437A1 (en) 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
RU2346935C2 (en) 2003-11-28 2009-02-20 Санкио Компани, Лимитед Derivative of cyclic amine, containing heteroaryl cycle
DE10361259A1 (en) 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of Rotigotine in Early Stage Parkinson's Disease to Prevent Further Neuronal Loss
CN1248690C (en) 2004-03-25 2006-04-05 华中师范大学 Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease
JP2007532562A (en) 2004-04-07 2007-11-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド Glucosamine and glucosamine / anti-inflammatory mutual prodrugs, compositions and methods
MEP25008A (en) 2004-04-29 2010-10-10 Caldwell Galer Inc Topical methadone compositions and methods for using the same
CN1672678A (en) 2004-05-03 2005-09-28 深圳微芯生物科技有限责任公司 Separation and extraction of natural active long-chain fatty acid component for preventing and treating prostatosis and the prepn and application of its medicine prepn
JP4781352B2 (en) 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド Levodopaprodrug and compositions thereof and uses thereof
CN100455560C (en) 2004-06-09 2009-01-28 中国人民解放军军事医学科学院放射医学研究所 Medicine precursor containing long chain fatty acyl group substituted venlafaxine and its prepn and use
AU2006225005A1 (en) 2005-03-18 2006-09-21 Ripped Formulations Ltd. Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
DK1704860T3 (en) * 2005-03-24 2011-02-07 Rottapharm Spa Benzamidine derivatives for the treatment and prevention of mucositis
BRPI0612796A2 (en) 2005-05-11 2010-11-30 Nycomed Gmbh combination of a pde4 inhibitor and a tetrahydrobiopterin derivative
DE102005022276A1 (en) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivatives of dihydroxyphenylalanine
WO2006125293A1 (en) 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
AU2006250335B2 (en) 2005-05-27 2010-09-02 Daiichi Sankyo Company, Limited Cyclic amine derivative having substituted alkyl group
EP1940398A1 (en) 2005-10-18 2008-07-09 Boehringer Ingelheim International GmbH Use of pramipexol for treating moderate to severe restless legs syndrome (rls)
CN101374552A (en) 2006-01-27 2009-02-25 旭化成制药株式会社 Medicine for transnasal administration
US20070259930A1 (en) 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
EP1870395A1 (en) 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Process for preparation of o-desmethylvenlafaxine and its analogue
US7943666B2 (en) 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
ES2611314T3 (en) 2006-12-14 2017-05-08 Knopp Biosciences Llc Compositions and procedures for using (R) -pramipexole
CN100573950C (en) 2006-12-14 2009-12-23 财团法人工业技术研究院 Phase change memory apparatus and manufacture method thereof
WO2008079404A2 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008089008A2 (en) 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Tetrahydrobiopterin prodrugs
ES2319024B1 (en) 2007-02-13 2009-12-11 Quimica Sintetica, S.A. PROCEDURE FOR OBTAINING ENTACAPONA SUBSTANTIALLY FREE OF ISOMERO Z, ITS SYNTHESIS INTERMEDIATES AND NEW CRYSTAL FORM.
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthesis of chirally purified substituted benzothiazole diamines
EP2522667B1 (en) 2007-05-01 2014-08-20 Concert Pharmaceuticals Inc. Morphinan compounds
EP1997493A1 (en) 2007-05-28 2008-12-03 Laboratorios del Dr. Esteve S.A. Combination of a 5-HT7 receptor ligand and an opioid receptor ligand
EP2190853A4 (en) 2007-06-22 2011-08-31 Gluconova Llc Halide-free glucosamine-acidic drug complexes
US20090075942A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fosamprenavir
CN101390854A (en) 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 Medical composition containing riluzole
WO2009056791A1 (en) 2007-11-02 2009-05-07 Pliva Hrvatska D.O.O. Processes for preparing pharmaceutical compounds
US20090118365A1 (en) 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
CN101186583B (en) 2007-12-20 2011-05-11 吉林大学 Methyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate and its synthesizing method and application
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
CN101569618B (en) 2008-04-30 2011-11-09 上海医药工业研究院 Application of long-chain fatty acid derivative or plant extracts containing same in inhibiting the activity of aromatizing enzyme
KR100990949B1 (en) 2008-06-09 2010-10-29 엔자이텍 주식회사 Method for Preparing Clopidogrel and Derivatives Thereof
LT2315740T (en) 2008-07-08 2018-02-26 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
PT2334378E (en) 2008-08-19 2014-07-16 Xenoport Inc Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
CN102170870A (en) 2008-08-22 2011-08-31 沃克哈特研究中心 An extended release pharmaceutical composition of entacapone or salts thereof
WO2010073124A2 (en) 2008-12-26 2010-07-01 Actavis Group Ptc Ehf Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
BRPI0901298A2 (en) 2009-04-06 2011-01-04 Ems Sa phthalimide derivatives of nonsteroidal antiinflammatory compounds and / or modulators of tnf- (alpha), process for obtaining them, pharmaceutical compositions containing them and their uses in the treatment of inflammatory diseases
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010147666A1 (en) 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
JP2013501733A (en) 2009-08-10 2013-01-17 ビーエイチアイ リミテッド パートナーシップ Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
CN102002053A (en) 2009-09-02 2011-04-06 陕西合成药业有限公司 Tetrahydro thienopyridine derivative for treating
CN101717392A (en) 2009-10-09 2010-06-02 苏州凯达生物医药技术有限公司 Method for preparing rotigotine and derivative thereof
CN102050815B (en) 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 Dabigatran ester derivatives as prodrug
CN101724934B (en) 2009-11-10 2012-07-04 东华大学 Medicinal fibre used for treating cutaneous inflammation and pain, preparation and application thereof
ES2364011B1 (en) 2009-11-20 2013-01-24 Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
CN102821602B (en) 2010-01-08 2016-04-20 凯特贝希制药公司 Fatty Acid Fumarate Derivative and uses thereof
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
RU2436772C2 (en) 2010-01-28 2011-12-20 Закрытое акционерное общество "НПК ЭХО" 4[(4'-nicotinoylamino)butyroylamino]butanoic acid, exhibiting nootropic activity, and method of producing said compound
US20130190327A1 (en) 2010-02-26 2013-07-25 Catabasis Pharmaceuticals Inc Bis-fatty acid conjugates and their uses
BR112012031194A2 (en) 2010-06-08 2018-05-29 Krisani Biosciences P Ltd cysteamine derivatives and their use in the treatment of ehna
EP2593094B1 (en) 2010-07-12 2017-12-06 Sanofi-Aventis Deutschland GmbH Aqueous composition comprising bromhexine
WO2012025213A2 (en) 2010-08-23 2012-03-01 Grünenthal GmbH Novel therapeutic compounds
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
CN101921245B (en) 2010-08-30 2012-04-18 中国人民解放军军事医学科学院卫生学环境医学研究所 Sulfonamides compound for inhibiting carbonic anhydrase II and synthesis method and application thereof
RS56713B1 (en) 2010-10-29 2018-03-30 Algiax Pharmaceuticals Gmbh Use of malononitrilamides in neuropathic pain
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2013008182A1 (en) 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
CN102336767A (en) 2011-07-11 2012-02-01 华东理工大学 Method for preparing high-purity chiral alpha-substituted-6,7-thiaindan[3,2-c]pyridine derivative
WO2013017974A1 (en) 2011-07-30 2013-02-07 Mahesh Kandula Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013024376A1 (en) 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
WO2013027150A1 (en) 2011-08-21 2013-02-28 Mahesh Kandula Compositions and methods for the treatment of parkinson's disease
CN102633799B (en) 2012-04-10 2014-06-25 凯莱英医药集团（天津）股份有限公司 Method for synthesizing sapropterin dihydrochloride from racemate intermediate separation route
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168022A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
US20150133533A1 (en) 2012-05-08 2015-05-14 Mahesh Kandula Compositions and methods for the treatment of cough
JP2015521184A (en) 2012-05-10 2015-07-27 セリックスビオ プライヴェート リミテッド Compositions and treatments for the treatment of metabolic syndrome

Also Published As

Publication number Publication date
CA2873104A1 (en) 2013-11-28
US9765020B2 (en) 2017-09-19
EP2852571A2 (en) 2015-04-01
CN104583182A (en) 2015-04-29
AU2013264820A1 (en) 2014-11-27
WO2013175377A3 (en) 2014-01-30
WO2013175377A2 (en) 2013-11-28
US20150307446A1 (en) 2015-10-29
ZA201408056B (en) 2016-04-28
EP2852571A4 (en) 2015-11-25
JP2015518855A (en) 2015-07-06

Similar Documents

Publication Publication Date Title
SG11201407326XA (en) Compositions and methods for treatment of mucositis
SG11201408094YA (en) Neprilysin inhibitors
SG11201407411SA (en) Compositions and methods for the treatment of metabolic syndrome
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201408539UA (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201805838UA (en) Macrocyclic mcl1 inhibitors for treating cancer
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201407319YA (en) Compositions and methods for treatment of inflammatory bowel disease
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201407458XA (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201407303SA (en) Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201407200TA (en) Liquid formulation
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201407317SA (en) Compositions and methods for suppression of carbonic anhydrase activity
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201808686VA (en) Synthesis of indazoles
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201902949PA (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201407323WA (en) Compositions and methods for the treatment of local pain